GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Additional Paid-In Capital

Kyverna Therapeutics (Kyverna Therapeutics) Additional Paid-In Capital : $523.73 Mil(As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics Additional Paid-In Capital?


Kyverna Therapeutics's quarterly additional paid-in capital increased from Sep. 2023 ($3.57 Mil) to Dec. 2023 ($4.64 Mil) and increased from Dec. 2023 ($4.64 Mil) to Mar. 2024 ($523.73 Mil).

Kyverna Therapeutics's annual additional paid-in capital increased from Dec. 2021 ($0.53 Mil) to Dec. 2022 ($1.71 Mil) and increased from Dec. 2022 ($1.71 Mil) to Dec. 2023 ($4.64 Mil).

Kyverna Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Kyverna Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics Additional Paid-In Capital Chart

Kyverna Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Additional Paid-In Capital
0.53 1.71 4.64

Kyverna Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial 1.71 - 3.57 4.64 523.73

Kyverna Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Kyverna Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Kyverna Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Kyverna Therapeutics (Kyverna Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Additional Paid-In Capital
Comparable Companies
Traded in Other Exchanges
N/A
Address
5980 Horton Street, STE 550, Emeryville, CA, USA, 94608
Website
https://www.kyvernatx.com
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR.

Kyverna Therapeutics (Kyverna Therapeutics) Headlines

From GuruFocus

Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering

By PRNewswire • 02-12-2024